Several studies have shown that CacyBP/SIP was notably overexpressed in pancreatic, colorectal, and breast cancer [14–16], while it was strongly decreased in gastric and renal carcinoma, where it was considered as a tumor suppressor [12, 13]. Here, CACYBP is linked to breast carcinoma.